AXSMAxsome Therapeutics, Inc.

$9B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$121M+62.0% YoY

Gross Profit

$112M91.9% margin

Operating Income

-$57M-46.9% margin

Net Income

-$59M-48.9% margin

EPS (Diluted)

$-1.22

QoQ Revenue Growth

+2.3%

Cash Flow

Operating Cash Flow

-$43M

Free Cash Flow

-$43M

Stock-Based Comp.

$23M

Balance Sheet

Total Assets

$597M

Total Liabilities

$543M

Stockholders' Equity

$53M

Cash & Equivalents

$301M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$121M	$75M	+62.0%
Gross Profit	$112M	$69M	+62.5%
Operating Income	-$57M	-$67M	+15.3%
Net Income	-$59M	-$68M	+13.1%

Revenue Segments

Product

$120M99%

Royalty

$1M1%

Geographic Segments

UNITED STATES

$119M99%

Non-US

$1M1%

AXSM Q1 2025 Earnings — Axsome Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena